Sigma Metric Analysis
A 2013 study evaluated the analytical performance of a POC blood analysis system. Are we seeing improvements in POC performance? Are there additional sources of error that need to be tracked when we evaluate POC devices?
As part of our continuing series of evaluations, we take a look at three point-of-care (POC) blood glucose analyzers. We use a paper that evaluates them for use in a specific critical setting: a neonatal intensive care unit.
A look at the UniCel DxI 800 Immunoassay Analyzer and its performance for five tumor markers.
Another chance to get a second look at instrument performance. Over a year ago, we looked at cancer marker performance on the Vista. Now we examine a 2012 study that compared the method performance of the new Vista methods vs. the older Immulite methods. How do the two generations of Siemens instrumentation compare? Do those results match the other study?
As part of our continuing series of evaluations, we take a look at two point-of-care (POC) HbA1c analyzers. As standards on performance have tightened, have POC devices kept up? Has their improved performance matched the higher demands?